Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4213119 | 0.89 | MAOB (0.39) | MAPT | |
| SCHEMBL7894528 | 0.84 | CES2 (0.39) | GAANPC1MAPTMDM2 | |
| SCHEMBL11415071 | 0.80 | TUBB4A (0.42) | TSHRSMN1; SMN2NPC1TP53MAPT | |
| SCHEMBL3649102 | 0.79 | EDNRB (0.32) | GAASMN1; SMN2MAPT | |
| SCHEMBL8559782 | 0.76 | TDO2 (0.38) | CYP1A2CYP3A4CYP2C9TSHRLMNA | |
| SCHEMBL11416663 | 0.76 | MEN1 (0.36) | ALOX15SMN1; SMN2MAPT | |
| SCHEMBL21533082 | 0.76 | MEN1 (0.36) | CYP1A2ALOX15TSHRLMNA | |
| SCHEMBL463373 | 0.72 | APEX1 (0.39) | CYP1A2TSHRMAPT | |
| SCHEMBL11412655 | 0.72 | METAP1 (0.40) | — | |
| SCHEMBL8780449 | 0.71 | BCHE (0.38) | CYP1A2CYP3A4CYP2C9LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6891041-B2 | Method for producing 4-(heteroaryl-methyl)-halogen-1(2H)-phthalazinones | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-05-10 | — | — | US | disclosed |
| US-20040192695-A1 | Method for producing 4-(heteroaryl-methyl)-halogen-1(2h)-phthalazinones | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-30 | — | — | US | disclosed |
| EP-1242405-B1 | METHOD FOR PRODUCING 4-(HETEROARYL-METHYL)-1(2H)-PHTHALAZINONES | SCHERING AG (DE) | 2004-08-18 | — | — | EP | disclosed |
| EP-1242405-A1 | METHOD FOR PRODUCING 4-(HETEROARYL-METHYL)-HALOGEN-1(2H)-PHTHALAZINONES | Schering Aktiengesellschaft (DE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001047912-A1 | METHOD FOR PRODUCING 4-(HETEROARYL-METHYL)-HALOGEN-1(2H)-PHTHALAZINONES | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192695-A1 | Method for producing 4-(heteroaryl-methyl)-halogen-1(2h)-phthalazinones | CYP4Z1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP19A1 1935/4885KCNQ2 1993/4885CYP1A2 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.